For decades, anticancer targeted therapies have been designed to inhibit kinases or other
enzyme classes and have profoundly benefited many patients. However, novel approaches …

Abstract Between 10% and 40% of newly diagnosed patients with acute myeloid leukemia
(AML) do not achieve complete remission with intensive induction therapy and are therefore …

Background The identification of oncogenic mutations in diffuse large B-cell lymphoma
(DLBCL) has led to the development of drugs that target essential survival pathways, but …

The combination of azacitidine and donor lymphocyte infusions (DLI) as first salvage therapy
for relapse after allogeneic transplantation (allo-HSCT) was studied in 30 patients with acute …

Lenalidomide is an effective therapeutic agent for multiple myeloma that exhibits
immunomodulatory properties including the activation of T and NK cells. The use of …

Lenalidomide, an antineoplastic and immunomodulatory drug, has therapeutic activity in
acute myeloid leukemia (AML), but definitive studies about its therapeutic utility have been …

Lenalidomide and azacitidine each have activity in myelodysplastic syndromes (MDS)
patients, where both microenvironment and cell-regulatory mechanisms contribute to …

Lenalidomide is a lead therapeutic in multiple myeloma and deletion 5q myelodysplastic
syndromes and shows promising activities in other hematologic malignancies. This article …

Patients with newly diagnosed multiple myeloma (NDMM) ineligible for autologous stem cell
transplantation (ASCT) have lower survival rates and may benefit from frontline regimens …

Functional interplay between acute myeloid leukemia (AML) cells and the bone marrow
microenvironment is a distinctive characteristic of this hematological cancer. Indeed, a large …